AstraZeneca’s MedImmune (UK) has published phase Ib study results in The Lancet Oncology. These showed anti-tumour activity of a combination of investigational antibodies in patients with lung cancer.
The trial considered patients undergoing treatment with durvalumab and tremelimumab, to see whether the drug combo could act therapeuticaly against locally advanced or metastatic non-small cell lung cancer (NSCLC), irrespective of PD-L1 status.
Less than half of patients with NSCLC have tumours that are PD-L1 positive, leaving a significant unmet medical need in the PD-L1 negative patient population.
A cohort of 26 patients who were PD-L1 positive and PD-L1 negative status were treated (22% and 29% Objective response rate respectively) resulting in an overall 23% response rate for both types.
Tremelimumab on the other hand inhibits the activity of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) to boost the immune response against cancer cells.